Advertisement
Paper| Volume 48, ISSUE 5, P549-558, December 01, 1987

Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of iow molecular weight heparinoid Org 10172 or heparin to rats

DOI:https://doi.org/10.1016/0049-3848(87)90386-0
Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of iow molecular weight heparinoid Org 10172 or heparin to rats
Previous ArticleImpaired thromboxane synthesis in preactivated human blood platelets: Agonist-specific, irreversible desensitization to thrombin
Next ArticlePlatelet storage lesion: Formation of platelet fragments with platelet factor 3 activity
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Time response curves of the anti-thrombotic effects, bleeding enhancing effects, effects on APTT, anti-Xa activities, anti-thrombin activities and thrombin generation inhibitory activities of the low molecular weight heparinoid Org 10172 and heparin have been compared in rats. The time courses of these effects were similar for heparin but quite different for Org 10172. Org 10172 induced anti-thrombotic and anti-Xa effects which lasted approximately 3 times longer than those at the same anti-xa doses of heparin, whereas the bleeding enhancing effects and effects on APTT of Org 10172 were of shorter duration than those of heparin. The half-life of the anti-thrombin effect after Org 10172 seemed somewhat longer than after heparin administration. Thrombin generation inhibition by Org 10172 showed a slightly longer duration than by heparin. The similarities between the time courses of the anti-thrombotic effect and the anti-Xa activity after Org 10172 administration suggest that the most appropriate parameter to monitor Org 10172 treatment is the plasma anti-Xa level.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Meuleman D.G.
        • Hobbelen P.M.J.
        • Van Dedem G.
        • Moelker H.C.T.
        A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
        Thromb. Res. 1982; 27: 353-363
        • Cade J.F.
        • Buchanan M.R.
        • Boneu B.
        • Ockelford P.
        • Carter C.J.
        • Cerskus A.L.
        • Hirsh J.
        A comparison of the anti-thrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.
        Thromb. Res. 1984; 35: 613-625
        • Boned B.
        • Buchanan M.R.
        • Cade J.F.
        • Van Rijn J.
        • Fernandez F.
        • Ofosu F.A.
        • Hirsh J.
        Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo.
        Thromb. Res. 1985; 40: 81-89
        • Buchanan M.R.
        • Ofosu F.A.
        • Fernandez F.
        • Van Rijn J.
        Lack of relationship between enhanced bleeding induced by heparin and other sulfated polysaccharides and enhanced catalysis of thrombin inhibition.
        Semin Thromb. Hemost. 1986; 12: 324-327
        • Hobbelen P.M.J.
        • Vogel G.M.T.
        • Princen A.W.M.
        • Meuleman D.G.
        Benefit (anti-thrombotic)/risk (bleeding) ratio of various heparin(oid)s in experimental models in rats.
        Thromb. Haemost. 1985; 54: 32
        • Hirsh J.
        • Ofosu F.
        • Buchanan M.
        Rationale behind the development of low molecular weight heparin derivatives.
        Semin. Thromb. Hemost. 1985; 11: 13-16
        • Tollefsen D.M.
        • Pestka C.A.
        • Monafo W.J.
        Activation of heparin cofactor II by dermatan sulfate.
        J. Biol. Chem. 1983; 258: 6713-6716

      8. VAN DINTHER, T.G., HOL. F. and MEULEMAN, D.G. Effects of various heparin(oid)s on heparin cofactor II mediated anti-thrombin activity and inhibition of thrombin generation in vitro (submitted for publication).

        • Fernandez F.
        • Van Rijn J.
        • Ofosu F.A.
        • Hirsh J.
        • Buchanan M.R.
        The haemorrhagic and anti-thrombotic effects of dermatan sulphate.
        Br. J. Haematol. 1986; 64: 309-317
        • Mikhailidis D.P.
        • Barradas M.A.
        • Mikhailidis A.M.
        • Magnani H
        • Dandona P.
        Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.
        Br. J. Clin. Pharmac. 1984; 17: 43-48
        • Umetsu T.
        • Sanai K.
        Effects of 1-methyl-3-mercapto-5-(3-pyridyl) imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats.
        Thromb. Haemost. 1978; 39: 74-83
        • Teien A.N.
        • Lie M.
        Evaluation of an amidolytic heparin assay method.
        in: Increased sensitivity by adding purified anti-thrombin III. ed. 9. Thromb. Res.10. 1977: 399-410
        • Larsen M.L.
        • Abildgaard U.
        • Teien A.N.
        • Gjesdal K.
        Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S2238).
        Thromb. Res. 1978; 13: 285-288
        • Ofosu F.A.
        • Modi G.J.
        • Smith L.M.
        • Cerskus A.L.
        • Hirsh J.
        • Blajchman M.A.
        Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
        Blood. 1984; 64: 727-747
        • Proctor R.R.
        • Rapaport S.I.
        The partial thromboplastin time with kaolin, a simple screening test for first stage plasma clotting factor deficiencies.
        Am. J. Clin. Pathol. 1961; 36: 212-219
        • De Swart C.A.M.
        • Nijmeyer B.
        • Roelofs J.M.M.
        • Sixma J.J.
        Kinetics of intravenously administered heparin in normal humans.
        Blood. 1982; 60: 1251-1258
        • Bara L.
        • Billand E.
        • Gramond G.
        • Kher A.
        • Samama M.
        Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration.
        Thromb. Res. 1985; 39: 631-636
        • Fareed J.
        • Kuman A.
        • Rock A.
        • Walenga J.M.
        • Davis P.
        A primate model (Macaca Mulatta) to study the pharmacokinetics of heparin and its fractions.
        Semin. Thromb. Hemost. 1985; 11: 138-154
        • Caranobe C.
        • Barret A.
        • Gabaig A.M.
        • Dupouy D.
        • Sie P.
        • Boned B.
        Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits.
        Thromb. Res. 1985; 40: 129-133
        • Carter C.J.
        • Kelton J.G.
        • Hirsh J.
        • Cerskus A.
        • Santos A.V.
        • Gent M.
        The relationship between the hemorrhagic and anti-thrombotic properties of low molecular weight heparin in rabbits.
        Blood. 1982; 59: 1239-1245
        • Doutremepuich C.
        • Bousquet F.
        • Toulemonde F.
        Are molecular weight and anti-Xa activity sufficient to predict the anti-thrombotic power of heparin fractions.
        Thromb. Res. 1986; 44: 709-712
        • Holmer E.
        • Mattson C.
        • Nilsson S.
        Anti-coagulant and anti-thrombotic effects of heparin and low molecular weight heparin fragments in rabbits.
        Thromb. Res. 1982; 25: 475-485
        • Ockelford P.A.
        • Carter C.J.
        • Mitchell L.
        • Hirsh J.
        Discordance between the anti-Xa activity and the anti-thrombotic activity of an ultra-low molecular weight heparin fraction.
        Thromb. Res. 1982; 28: 401-409
        • Buchanan M.R.
        • Boneu B.
        • Ofosu F.
        • Hirsh J.
        The relative importance of thrombin inhibition and factor Xa inhibition to the anti-thrombotic effects of heparin.
        Blood. 1985; 65: 198-201
        • McAvoy T.J.
        The biologic half-life of heparin.
        Clin. Pharmacol. Ther. 1979; 25: 372-379
        • Bjornsson T.D.
        • Levy G.
        Pharmacokinetics of heparin. II. Studies of time dependence in rats.
        J. Pharmacol. Exp. Ther. 1979; 210: 243-246
        • Cocchetto D.M.
        • Bjornsson T.D.
        Progress toward an understanding of the anticoagulant effect and pharmacokinetics of heparin.
        Pharm. Int. 1984; 5: 7-11

      Article info

      Publication history

      Accepted: October 6, 1987
      Received: August 25, 1987

      Identification

      DOI: https://doi.org/10.1016/0049-3848(87)90386-0

      Copyright

      © 1987 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX